Overview

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation containing two FDA-approved drugs in HIV-infected patients who have not received prior therapy. This tablet will be taken with one of two FDA-approved drugs as a once-daily regimen. Study physicians will evaluate subjects to determine if they have certain medical conditions, laboratory test values, medication use, or drug allergies that would exclude them from the study.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Abacavir
Efavirenz
Lamivudine
Tenofovir